降低了突触囊糖蛋白2A结合在人死后的基本小脑:减少突触密度的证据
Yanghong Yang1, Chao Zheng1, Baosheng Chen1
1Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, USA.
Cerebellum (London, England)
|October 2, 2023
概括
基本震 (ET) 显示小脑内突触密度降低. 这项试点研究在ET病例中发现突触囊糖蛋白2A (SV2A) 显著降低,这表明这种神经疾病的潜在生物标志物.
科学领域:
- 神经科学是一个神经科学.
- 神经病理学神经病理学
- 放射化学 放射化学是指辐射化学.
背景情况:
- 基本震 (ET) 是一种常见的神经疾病,其病理生理学不清楚.
- 虽然小脑变化与ET有关,但传统的神经成像缺乏神经退行症的明确特征.
- 以前的ET神经病理学研究没有关注突触标记物.
研究的目的:
- 为了研究死后基本震 (ET) 病例中的突触密度.
- 评估突触囊糖蛋白2A (SV2A) 作为小脑突触密度的测量.
- 探索潜在的神经成像生物标志物用于外星人.
主要方法:
- 使用SV2A无线电配体[18F]SDM-16.6进行体外自发辐射.
- 评估小脑皮层和牙状核中的突触密度.
- 将三个ET病例与三个年龄相匹配的对照进行了比较.
主要成果:
- 在ET病例中,突触囊泡糖蛋白2A (SV2A) 水平显著降低.
- 与对照组相比,ET患者的大脑小皮层中的SV2A水平降低了53%.
- 与对照组相比,ET患者的牙状核中SV2A的含量降低了46%.
结论:
- 这项试点研究表明,ET患者大脑中突触密度显著降低.
- 研究结果表明,SV2A成像可以作为一种有价值的基本震生物标志物.
- 未来的研究应该涉及更大的样本大小和体内成像研究.
相关概念视频
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
332
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
332
Fusion of Secretory Vesicles with the Plasma Membrane
11.1K
Proteins and neurotransmitters in secretory vesicles can be released from a cell upon vesicle docking, priming, and fusion with the plasma membrane. Vesicles are docked and primed in preparation for the quick exocytosis of their contents in response to a stimulus. The fusion process is mainly carried out by a SNAP Receptor or SNARE complex, consisting of synaptobrevin, syntaxin-1, and SNAP-25.
In 1993, Jim Rothman proposed that the antiparallel pairing of vesicular and transmembrane SNAREs, or...
In 1993, Jim Rothman proposed that the antiparallel pairing of vesicular and transmembrane SNAREs, or...
11.1K
Chemical Synapses
8.9K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
8.9K
Drugs Affecting Neurotransmitter Release or Uptake
1.1K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.1K
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Long-term Depression
2.6K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.6K


